CL2020003331A1 - Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2 - Google Patents
Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2Info
- Publication number
- CL2020003331A1 CL2020003331A1 CL2020003331A CL2020003331A CL2020003331A1 CL 2020003331 A1 CL2020003331 A1 CL 2020003331A1 CL 2020003331 A CL2020003331 A CL 2020003331A CL 2020003331 A CL2020003331 A CL 2020003331A CL 2020003331 A1 CL2020003331 A1 CL 2020003331A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitors
- cannabinoid receptor
- pyrazine compounds
- new pyridine
- pyridine
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 title 1
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003216 pyrazines Chemical class 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
Abstract
La invención se refiere a un compuesto de fórmula (I); en donde A1, A2, X y R1-R3 son como se definen en la descripción y en las reivindicaciones. El compuesto de fórmula (I) puede usarse como un medicamento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18180137 | 2018-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003331A1 true CL2020003331A1 (es) | 2021-05-07 |
Family
ID=62814868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003331A CL2020003331A1 (es) | 2018-06-27 | 2020-12-21 | Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12071420B2 (es) |
| EP (1) | EP3814329B1 (es) |
| JP (1) | JP7445610B2 (es) |
| KR (1) | KR102790077B1 (es) |
| CN (2) | CN112262132A (es) |
| AU (2) | AU2019294256B2 (es) |
| BR (1) | BR112020025013A2 (es) |
| CA (1) | CA3096777A1 (es) |
| CL (1) | CL2020003331A1 (es) |
| CO (1) | CO2020011855A2 (es) |
| CR (1) | CR20200643A (es) |
| IL (1) | IL279725B2 (es) |
| MA (1) | MA53002A (es) |
| MX (1) | MX2020012760A (es) |
| PE (1) | PE20210368A1 (es) |
| PH (1) | PH12020552152A1 (es) |
| SG (1) | SG11202009103WA (es) |
| WO (1) | WO2020002320A1 (es) |
| ZA (1) | ZA202005426B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006030671B4 (de) | 2006-07-04 | 2008-10-02 | Moeller Gmbh | Schutzschalter-Kurzschließer-Kombination |
| TW201904943A (zh) | 2017-06-20 | 2019-02-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎吡啶衍生物 |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| CA3096777A1 (en) | 2018-06-27 | 2020-02-02 | F. Hoffmann-La Roche Ag | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| EP3814337B1 (en) | 2018-06-27 | 2025-05-14 | F. Hoffmann-La Roche AG | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
| JP7478672B2 (ja) | 2018-06-27 | 2024-05-07 | エフ． ホフマン－ラ ロシュ アーゲー | カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物 |
| EP4423256A2 (en) | 2021-10-28 | 2024-09-04 | Genentech, Inc. | Systems and methods to identify mhc-associated antigens for therapeutic intervention |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3775685B2 (ja) | 1993-07-28 | 2006-05-17 | ローン−プーラン・ロレ・リミテツド | Ｐｄｅ▲ｉｖ▼およびｔｎｆ抑制剤としての化合物 |
| GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| DE602005009500D1 (de) * | 2004-02-24 | 2008-10-16 | Glaxo Group Ltd | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors |
| GB0418047D0 (en) | 2004-08-12 | 2004-09-15 | Syngenta Participations Ag | Fungicidal compositions |
| WO2006105217A2 (en) | 2005-03-31 | 2006-10-05 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
| FR2887550A1 (fr) | 2005-06-24 | 2006-12-29 | Sanofi Aventis Sa | Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique |
| DK1940821T3 (da) | 2005-10-19 | 2013-06-10 | Gruenenthal Gmbh | Nye vanilloid-receptorligander og deres anvendelse til fremstilling af lægemidler. |
| CN101522644B (zh) * | 2006-10-04 | 2013-04-24 | 霍夫曼-拉罗奇有限公司 | 作为cb2受体调节剂的吡嗪-2-羧酰胺衍生物 |
| EP2311443A1 (en) | 2009-10-15 | 2011-04-20 | Rheinische Friedrich-Wilhelms-Universität | Pharmaceutical composition containing cannabinoid-receptor 2 antagonists |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| BR112014004310B8 (pt) | 2011-08-25 | 2023-04-18 | Merck Sharp & Dohme | Composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto |
| US9403808B2 (en) | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
| WO2014071361A1 (en) | 2012-11-05 | 2014-05-08 | Rubicon Genomics | Barcoding nucleic acids |
| SI2928882T1 (sl) | 2012-12-07 | 2017-05-31 | F. Hoffmann-La Roche Ag | Pirazinski derivati kot agonisti receptorja CB2 |
| HRP20171459T1 (hr) | 2012-12-07 | 2017-11-03 | F. Hoffmann - La Roche Ag | Piridin-2-amidi korisni kao agonisti cb2 |
| HRP20180672T1 (hr) | 2012-12-07 | 2018-06-01 | F. Hoffmann - La Roche Ag | Novi derivati piridina |
| JP6426619B2 (ja) * | 2012-12-07 | 2018-11-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｂ２アゴニストとして有用なピリジン−２−アミド |
| PE20151559A1 (es) | 2013-03-26 | 2015-11-05 | Hoffmann La Roche | Nuevos derivados de piridina |
| CN106132958A (zh) | 2014-04-04 | 2016-11-16 | 豪夫迈·罗氏有限公司 | 作为cb2激动剂的吡啶‑2‑酰胺类化合物 |
| MX2016012690A (es) * | 2014-04-04 | 2017-04-27 | Hoffmann La Roche | Piridin-2-carboxamidas 5,6-disustituidas como agonistas del receptor cannabinoide. |
| WO2016066534A1 (en) | 2014-10-27 | 2016-05-06 | F. Hoffmann-La Roche Ag | Radiolabeled cannabinoid receptor 2 ligand |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| SI3386951T1 (sl) | 2015-12-09 | 2020-07-31 | F. Hoffmann-La Roche Ag | Fenilni derivati kot agonisti kanabinoidnega receptorja 2 |
| IL269431B2 (en) | 2017-03-23 | 2025-05-01 | Univ Washington | Methods for targeted nucleic acid sequence enrichment with applications to error corrected nucleic acid sequencing |
| TW201906818A (zh) | 2017-05-31 | 2019-02-16 | 美商５１１製藥公司 | 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用 |
| TW201904943A (zh) | 2017-06-20 | 2019-02-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎吡啶衍生物 |
| KR20210010475A (ko) | 2018-05-15 | 2021-01-27 | 룬드벡 라 졸라 리서치 센터 인코포레이티드 | Magl 저해제 |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| EP3814337B1 (en) | 2018-06-27 | 2025-05-14 | F. Hoffmann-La Roche AG | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
| CA3096777A1 (en) | 2018-06-27 | 2020-02-02 | F. Hoffmann-La Roche Ag | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| JP7478672B2 (ja) | 2018-06-27 | 2024-05-07 | エフ． ホフマン－ラ ロシュ アーゲー | カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物 |
| TWI687701B (zh) | 2018-12-05 | 2020-03-11 | 宏碁股份有限公司 | 判斷電量狀態的方法及其電子裝置 |
-
2019
- 2019-06-25 CA CA3096777A patent/CA3096777A1/en active Pending
- 2019-06-25 BR BR112020025013-9A patent/BR112020025013A2/pt unknown
- 2019-06-25 EP EP19733484.0A patent/EP3814329B1/en active Active
- 2019-06-25 CR CR20200643A patent/CR20200643A/es unknown
- 2019-06-25 CN CN201980025482.7A patent/CN112262132A/zh active Pending
- 2019-06-25 SG SG11202009103WA patent/SG11202009103WA/en unknown
- 2019-06-25 KR KR1020217001909A patent/KR102790077B1/ko active Active
- 2019-06-25 AU AU2019294256A patent/AU2019294256B2/en active Active
- 2019-06-25 JP JP2020568525A patent/JP7445610B2/ja active Active
- 2019-06-25 MA MA053002A patent/MA53002A/fr unknown
- 2019-06-25 CN CN202411199620.2A patent/CN119161323A/zh active Pending
- 2019-06-25 MX MX2020012760A patent/MX2020012760A/es unknown
- 2019-06-25 PE PE2020001433A patent/PE20210368A1/es unknown
- 2019-06-25 IL IL279725A patent/IL279725B2/en unknown
- 2019-06-25 WO PCT/EP2019/066811 patent/WO2020002320A1/en not_active Ceased
-
2020
- 2020-08-31 ZA ZA2020/05426A patent/ZA202005426B/en unknown
- 2020-09-24 CO CONC2020/0011855A patent/CO2020011855A2/es unknown
- 2020-12-14 PH PH12020552152A patent/PH12020552152A1/en unknown
- 2020-12-17 US US17/125,650 patent/US12071420B2/en active Active
- 2020-12-21 CL CL2020003331A patent/CL2020003331A1/es unknown
-
2024
- 2024-07-26 US US18/785,279 patent/US20240383872A1/en active Pending
- 2024-09-12 AU AU2024219640A patent/AU2024219640A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202005426B (en) | 2025-06-25 |
| PH12020552152A1 (en) | 2021-07-05 |
| MX2020012760A (es) | 2021-03-25 |
| KR20210028202A (ko) | 2021-03-11 |
| AU2019294256A1 (en) | 2020-09-24 |
| CR20200643A (es) | 2021-05-11 |
| SG11202009103WA (en) | 2020-10-29 |
| KR102790077B1 (ko) | 2025-04-03 |
| US20240383872A1 (en) | 2024-11-21 |
| AU2024219640A1 (en) | 2024-10-03 |
| US12071420B2 (en) | 2024-08-27 |
| CN112262132A (zh) | 2021-01-22 |
| IL279725B1 (en) | 2023-12-01 |
| EP3814329C0 (en) | 2024-01-17 |
| CA3096777A1 (en) | 2020-02-02 |
| EP3814329B1 (en) | 2024-01-17 |
| CO2020011855A2 (es) | 2020-10-20 |
| EP3814329A1 (en) | 2021-05-05 |
| WO2020002320A1 (en) | 2020-01-02 |
| MA53002A (fr) | 2021-05-05 |
| IL279725A (en) | 2021-03-01 |
| AU2019294256B2 (en) | 2024-06-20 |
| JP2021529157A (ja) | 2021-10-28 |
| IL279725B2 (en) | 2024-04-01 |
| PE20210368A1 (es) | 2021-02-26 |
| CN119161323A (zh) | 2024-12-20 |
| BR112020025013A2 (pt) | 2021-03-23 |
| JP7445610B2 (ja) | 2024-03-07 |
| US20210115011A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003331A1 (es) | Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2 | |
| UY37623A (es) | Derivados de oxadiazol tiofeno fungicidas | |
| UY35975A (es) | Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia | |
| MX373247B (es) | Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina. | |
| CL2022001492A1 (es) | Nuevos inhibidores de braf como rompedores de la paradoja | |
| MX390347B (es) | Compuestos de aminotiazol como inhibidores de c-kit. | |
| CO2019011967A2 (es) | Compuestos antitumorales | |
| UY36999A (es) | Derivados de aryl oxadiazol fungicidas | |
| MX2018015212A (es) | Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| CL2018000953A1 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
| BR112017026682A2 (pt) | novos compostos bicíclicos como inibidores de dupla ação de atx/ca | |
| MX376056B (es) | Pirimidinonas como inhibidores del factor xia. | |
| MX2018000880A (es) | Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r). | |
| EA201892838A1 (ru) | Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их | |
| BR112018012390A2 (pt) | derivados de oxadiazol microbiocidas | |
| ECSP18024565A (es) | Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas | |
| EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
| BR112019001229A2 (pt) | derivados de oxadiazol microbiocida | |
| BR112018008467A2 (pt) | derivados de oxadiazol microbiocidas | |
| BR112018012825A2 (pt) | derivados de oxadiazol microbiocidas | |
| CO2018004573A2 (es) | Derivados de fenilo como agonistas del receptor 2 de cannabinoides | |
| BR112018074943A2 (pt) | derivados de oxadiazol microbiocidas | |
| UY37912A (es) | Derivados de picolinamida fungicidas que portan grupos terminales heteroarilo o heteroariloxi | |
| MX2020007565A (es) | Nuevos oxadiazoles. | |
| BR112019000942A2 (pt) | derivados de oxadiazol microbiocida |